{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:56:45Z","timestamp":1787021805850,"version":"build-2736575974"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swiss National Science Fundation","award":["166819, 17481"],"award-info":[{"award-number":["166819, 17481"]}]},{"DOI":"10.13039\/501100010474","name":"Swiss HIV Cohort Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010474","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"\n Background<\/jats:title>\n Dolutegravir (DTG)\u2013based dual therapy is becoming a new paradigm for both the initiation and maintenance of HIV treatment. The SIMPL\u2019HIV study investigated the outcomes of virologically suppressed patients on standard combination antiretroviral therapy (cART) switching to DTG + emtricitabine (FTC). We present the 48-week efficacy and safety data on DTG + FTC versus cART.<\/jats:p>\n <\/jats:sec>\n \n Methods and findings<\/jats:title>\n \n SIMPL\u2019HIV was a multicenter, open-label, non-inferiority randomized trial with a factorial design among treatment-experienced people with HIV in Switzerland. Participants were enrolled between 12 May 2017 and 30 May 2018. Patients virologically suppressed for at least 24 weeks on standard cART were randomized 1:1 to switching to DTG + FTC or to continuing cART, and 1:1 to simplified patient-centered monitoring versus standard monitoring. The primary endpoint was the proportion of patients virologically suppressed with <100 copies\/ml through 48 weeks. The secondary endpoints included virological suppression at 48 weeks according to the US Food and Drug Administration (FDA) snapshot analysis. Non-inferiority of DTG + FTC versus cART for viral suppression was assessed using a stratified Mantel\u2013Haenszel risk difference, with non-inferiority declared if the lower bound of the 95% confidence interval was greater than \u221212%. Adverse events were monitored to assess safety. Quality of life was evaluated using the PROQOL-HIV questionnaire. Ninety-three participants were randomized to DTG + FTC, and 94 individuals to cART. Median nadir CD4 count was 246 cells\/mm\n 3<\/jats:sup>\n ; median age was 48 years; 17% of participants were female. DTG + FTC was non-inferior to cART. The proportion of patients with viral suppression (<100 copies\/ml) through 48 weeks was 93.5% in the DTG + FTC arm and 94.7% in the cART arm in the intention-to-treat population (risk difference \u22121.2%; 95% CI \u22127.8% to 5.6%). Per-protocol analysis showed similar results, with viral suppression in 96.5% of patients in both arms (risk difference 0.0%; 95% CI \u22125.6% to 5.5%). There was no relevant interaction between the type of treatment and monitoring (interaction ratio 0.98; 95% CI 0.85 to 1.13;\n p<\/jats:italic>\n = 0.81). Using the FDA snapshot algorithm, 84\/93 (90.3%) participants in the DTG + FTC arm had an HIV-1 RNA viral load of <50 copies\/ml compared to 86\/94 (91.5%) participants on standard cART (risk difference \u22121.1%; 95% CI \u22129.3% to 7.1%;\n p<\/jats:italic>\n = 0.791). The overall proportion of patients with adverse events and discontinuations did not differ by randomization arm. The proportion of patients with serious adverse events was higher in the cART arm (16%) compared to the DTG + FTC arm (6.5%) (\n p<\/jats:italic>\n = 0.041), but none was considered to be related to the study medication. Quality of life improved more between baseline and week 48 in the DTG + FTC compared to the cART arm (adjusted difference +2.6; 95% CI +0.4 to +4.7). The study\u2019s main limitations included a rather small proportion of women included, the open label design, and its short duration.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this study, DTG + FTC as maintenance therapy was non-inferior to cART in terms of efficacy, with a similar safety profile and a greater improvement in quality of life, thus expanding the offer of 2-drug simplification options among virologically suppressed individuals.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n ClinicalTrials.gov\n NCT03160105<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003421","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T13:39:19Z","timestamp":1605015559000},"page":"e1003421","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL\u2019HIV trial"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-9813","authenticated-orcid":true,"given":"Delphine","family":"Sculier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-696X","authenticated-orcid":true,"given":"Sabine","family":"Yerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-0044","authenticated-orcid":true,"given":"Annalisa","family":"Marinosci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0088-5078","authenticated-orcid":true,"given":"Marcel","family":"Stoeckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-8373","authenticated-orcid":true,"given":"Enos","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique L.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Vernazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-7833","authenticated-orcid":true,"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Buzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-1503","authenticated-orcid":true,"given":"Karin J.","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-1325","authenticated-orcid":true,"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-6723","authenticated-orcid":true,"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-9476","authenticated-orcid":true,"given":"Andreas","family":"Limacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-5132","authenticated-orcid":true,"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the Swiss HIV Cohort Study (SHCS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"pmed.1003421.ref001","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2020"},{"key":"pmed.1003421.ref002","volume-title":"EACS guidelines 2020. Version 10.1","author":"European AIDS Clinical Society","year":"2020"},{"issue":"2","key":"pmed.1003421.ref003","doi-asserted-by":"crossref","first-page":"e0148231","DOI":"10.1371\/journal.pone.0148231","article-title":"Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients","volume":"11","author":"JG Baril","year":"2016","journal-title":"PLoS ONE"},{"issue":"11","key":"pmed.1003421.ref004","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"ML Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"pmed.1003421.ref005","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"I Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"pmed.1003421.ref006","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.1","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis","volume":"7","author":"G Wandeler","year":"2018","journal-title":"F1000Res"},{"issue":"10167","key":"pmed.1003421.ref007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"P Cahn","year":"2019","journal-title":"Lancet"},{"key":"pmed.1003421.ref008","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study","author":"J van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pmed.1003421.ref009","unstructured":"Reynes J, Meftah N, Tuaillon E, Charpentier C, Montes B. Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study. 9th IAS Conference on HIV Science; 2017 Jul 23\u201326; Paris, France."},{"key":"pmed.1003421.ref010","unstructured":"Mascolini M. Maintenance DTG\/3TC controls HIV in people with historical 3TC resistance \u201cDolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)\u201d. 17th European AIDS Conference; 2019 Nov 6\u20139; Basel, Switzerland."},{"issue":"11","key":"pmed.1003421.ref011","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/379667","article-title":"Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients","volume":"188","author":"FS Rousseau","year":"2003","journal-title":"J Infect Dis"},{"issue":"5","key":"pmed.1003421.ref012","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ije\/dyp321","article-title":"Cohort profile: the Swiss HIV Cohort study","volume":"39","author":"F Schoeni-Affolter","year":"2010","journal-title":"Int J Epidemiol"},{"key":"pmed.1003421.ref013","volume-title":"EACS guidelines. Version 9.0","author":"European AIDS Clinical Society","year":"2017"},{"key":"pmed.1003421.ref014","volume-title":"HIV-1 genotypic drug resistance interpretation\u2019s algorithms","author":"French National Agency for AIDS Research","year":"2020"},{"issue":"Part B","key":"pmed.1003421.ref015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.trac.2016.03.019","article-title":"The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine","volume":"84","author":"LA Decosterd","year":"2016","journal-title":"TrAC Trends Anal Chem"},{"issue":"5","key":"pmed.1003421.ref016","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jms.3200","article-title":"A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients","volume":"48","author":"M Aouri","year":"2013","journal-title":"J Mass Spectrom"},{"key":"pmed.1003421.ref017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clinms.2018.04.001","article-title":"Determination of nucleosidic\/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry","volume":"8","author":"P Courlet","year":"2018","journal-title":"Clin Mass Spectrom"},{"key":"pmed.1003421.ref018","volume-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0","author":"Division of AIDS","year":"2014"},{"key":"pmed.1003421.ref019","volume-title":"Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for industry","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research","year":"2015"},{"issue":"5","key":"pmed.1003421.ref020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0b013e318245cafe","article-title":"The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV\/AIDS","volume":"59","author":"M Duracinsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pmed.1003421.ref021","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/QAI.0b013e31824be3f2","article-title":"Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease","volume":"59","author":"M Duracinsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4 Suppl 3","key":"pmed.1003421.ref022","doi-asserted-by":"crossref","first-page":"19793","DOI":"10.7448\/IAS.17.4.19793","article-title":"Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis","volume":"17","author":"HJ Stellbrink","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pmed.1003421.ref023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"JL Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9712","key":"pmed.1003421.ref024","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"JJ Eron","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"pmed.1003421.ref025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","author":"M Bonnet","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pmed.1003421.ref026","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial","volume":"14","author":"JR Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pmed.1003421.ref027","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial","volume":"15","author":"JR Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pmed.1003421.ref028","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/jac\/dkw031","article-title":"Atazanavir\/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial","volume":"71","author":"L Galli","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4 Suppl 3","key":"pmed.1003421.ref029","doi-asserted-by":"crossref","first-page":"19809","DOI":"10.7448\/IAS.17.4.19809","article-title":"Randomized trial of DRV\/r or LPV\/r QD monotherapy vs maintaining a PI\/r-based antiretroviral regimen in persons with suppressed HIV replication","volume":"17","author":"C Pinnetti","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"pmed.1003421.ref030","volume-title":"Non-inferiority clinical trials to establish effectiveness. Guidance for industry","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research","year":"2016"},{"issue":"7382","key":"pmed.1003421.ref031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"DG Altman","year":"2003","journal-title":"BMJ"},{"issue":"1649","key":"pmed.1003421.ref032","doi-asserted-by":"crossref","first-page":"20130249","DOI":"10.1098\/rstb.2013.0249","article-title":"Studying morphological integration and modularity at multiple levels: concepts and analysis","volume":"369","author":"CP Klingenberg","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"pmed.1003421.ref033","volume-title":"R software. Version 3.6.1","author":"R Core Team","year":"2019"},{"key":"pmed.1003421.ref034","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"KF Schulz","year":"2010","journal-title":"BMC Med"},{"issue":"10123","key":"pmed.1003421.ref035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"JM Llibre","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"pmed.1003421.ref036","doi-asserted-by":"crossref","first-page":"ofw053","DOI":"10.1093\/ofid\/ofw053","article-title":"Evaluation of serum creatinine changes with integrase inhibitor use in human immunodeficiency virus-1 infected adults","volume":"3","author":"TA Lindeman","year":"2016","journal-title":"Open Forum Infect Dis"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T13:39:51Z","timestamp":1605015591000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003421"}},"subtitle":[],"editor":[{"given":"Marie-Louise","family":"Newell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003421","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}